
News|Articles|May 1, 2005
First-time generic approvals
Anti-sense compound (LR3001, Genta) for the treatment of chronic myelocytic leukemia
Advertisement
Dantrolene capsules 25, 50, and 100 mg (equiv to Dantrium capsules)
IMPAX
Griseofulvin oral suspension 125 mg/5 mL (equiv to Grifuvin V)
STIEFEL
Octreotide injection (preservative free) 0.05, 0.1, and 0.5 mg/mL (equiv to Sandostatin)
BEDFORD
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first postmenopausal libido treatment, Addyi
2
What IRA drug prices will mean for PBMs, health plans and patients
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
Biosimilars in 2025: A year of firsts
5






















































